Patient-Derived Cell Lines Improve Clinical Relevance
Patient-derived human primary cell-based assays are developed from either tissue, blood from healthy donors or with defined disease characteristics to predict translational clinical relevance. Over the years, Charles River has established a network of collaborators to access patient-derived cells across numerous therapeutic areas such as Fibrosis and Oncology.
Integrating patient-derived cells into translational research
- CRISPR/Cas9 editing capabilities combining these patient-derived cells with our CRISPR/Cas9 platform allows generation of the most relevant cell systems; those with mutations, reporters, or isogenic controls
- Biochemical and functional cell-based assays to mimic the diseased cellular environment
- High-content imaging screening and profiling platforms disease state insight at the subcellular
- Therapeutic area applications scientific expertise in for more than 20 disease indications
- Mechanism of action studies using adenoviral SilenceSelect® and FLeXSelect® libraries
- Protein (Luminex, MesoScale) and RNA (qPCR, digital droplet PCR, and NGS) readouts
RNA Fluorescence In Situ Hybridization by High-Content Imaging
Patient-Derived Cells - Frequently Asked Questions (FAQ’s)
How are patient-derived cells impacting drug discovery?
Screening with patient-derived cells in place of immortal cells lines provides disease related, translation insights at the earliest point in the drug discovery process. Read this example of how patient-derived cells provide new drug-screening method for schizophrenia.
What are the sources of patient-derived cells?
Charles River has an established a wide network to obtain donated diseased tissue and blood cells. Our own staff routinely supply samples of healthy blood, ensuring a consistent source, reducing variables.
Are all patient-derived cells diseased cells?
Patient-derived cells come from both healthy donors and donors with disease characteristics. This enables readouts that monitor and compare compound interactions in healthy and diseased biologically relevant environments.